Document › Details

Oxford BioMedica plc. (8/17/17). "Press Release: Interim Results for the Six Months Ended 30 June 2017". Oxford.

Organisations Organisation Oxford BioMedica plc (LSE: OXB)
  Group Oxford BioMedica (Group)
  Organisation 2 Innovate UK
  Group United Kingdom (GB) (govt)
Products Product LentiVector® technology
  Product 2 tisagenlecleucel-T (CTL019)
  Index term 2 Novartis–Oxford BioMedica: lentiviral vector technology, 201703 supply existent OBM sole producer of lentiviral vector expressing CTL019
Persons Person Dawson, John (Oxford BioMedica 200810– CEO before Cephalon Europe)
  Person 2 Nolan, Peter (Oxford BioMedica 200507)

Record changed: 2017-08-24


Picture [LSUK] – The Business Web Portal 650x99px

More documents for Oxford BioMedica (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] – Putting Information into Context 600x60px

» top